KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares Outstanding
Ratios

Biogen (BIIB) Shares Repurchased (2016 - 2022)

Biogen has reported Shares Repurchased over the past 14 years, most recently at $250.0 million for Q3 2022.

  • For Q3 2022, Shares Repurchased fell 66.67% year-over-year to $250.0 million; the TTM value through Dec 2023 reached $250.0 million, down 66.67%, while the annual FY2022 figure was $750.0 million, 58.33% down from the prior year.
  • Shares Repurchased for Q3 2022 was $250.0 million at Biogen, down from $500.0 million in the prior quarter.
  • Over five years, Shares Repurchased peaked at $3.7 billion in Q2 2020 and troughed at $250.0 million in Q1 2018.
  • A 5-year average of $1.2 billion and a median of $733.9 million in 2019 define the central range for Shares Repurchased.
  • Biggest five-year swings in Shares Repurchased: surged 251.75% in 2018 and later tumbled 87.84% in 2021.
  • Year by year, Shares Repurchased stood at $1.4 billion in 2018, then surged by 54.75% to $2.1 billion in 2019, then plummeted by 80.89% to $400.0 million in 2020, then surged by 87.5% to $750.0 million in 2021, then plummeted by 66.67% to $250.0 million in 2022.
  • Business Quant data shows Shares Repurchased for BIIB at $250.0 million in Q3 2022, $500.0 million in Q2 2022, and $750.0 million in Q3 2021.